ClinicalTrials.gg
CompletedNCT03985943Updated Aug 14, 2024Results posted

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Placebo and Nemolizumab in Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D. Completed at 174 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
941
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
2nd of 14
941 · median 209
Started
2019
with 3 others
Phase 3
5 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Read the detailed description

This was a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent subjects of age 12 years and above with moderate-to-severe AD. Eligible subjects had a documented history of inadequate response to topical AD medication(s). Approximately 750 subjects were randomized in 2:1 to receive either nemolizumab or placebo, stratified by baseline disease severity (Investigator's Global Assessment (IGA) = 3, moderate; IGA = 4, severe) and peak pruritus numeric rating scale (PP NRS) severity (PP NRS >= 7; PP NRS \< 7). A minimum of 250 subjects were randomized in each PP NRS strata. All nemolizumab-treated subjects who were clinical responders at Week 16 (i.e., the end of initial treatment [Initial Treatment Period]/beginning of Maintenance Period) were re-randomized (1:1:1) to different treatment regimens (nemolizumab injections Q4W or every 8 weeks (Q8W) [with placebo injections at Weeks 20, 28, 36, and 44 to maintain the blind] or placebo Q4W). A clinical responder was defined as a subject at Week 16 with an IGA of 0 (clear) or 1 (almost clear) or a >= 75% improvement in EASI from baseline (EASI-75). All placebo-treated subjects who responded to placebo during the Initial Treatment Period continued to receive placebo Q4W in the Maintenance Period.

03

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis

Browse trials for

Keywords

  • CD14152
  • Nemolizumab
  • Atopic Dermatitis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects aged greater than and equal to (>=) 12 years at the screening visit.
  • Chronic atopic dermatitis (according to American Academy of Dermatology Consensus Criteria) that has been present for at least 2 years before the screening visit.
  • Eczema Area and Severity Index (EASI) score >=16 at the screening and baseline visits.
  • Investigator Global Assessment (IGA) score >= 3 (scale of 0 to 4) at the screening and baseline visits.
  • AD involvement >= 10 percent (%) of body surface area (BSA) at screening and baseline visits.
  • Peak Pruritus Numerical Rating Scale (PPNRS) score of at least 4.0 at the screening and baseline visit.
  • Documented recent history of inadequate response to topical medications (topical [TCS] with or without Topical calcineurin inhibitors [TCI]).
  • Female subjects of (that is, fertile, following menarche and until becoming unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an adequate and approved method of throughout the study and for 12 weeks after the last study drug injection.

Key Exclusion Criteria:

  • Body weight (\<) 30 kilograms (kg).
  • Exacerbation of asthma requiring hospitalization in the preceding 12 months. Uncontrolled asthma in the preceding 3 months.
  • Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit.
  • Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.

Note: Subjects with chronic, stable use of prophylactic treatment for recurrent herpes viral infection can be included in this clinical study.

  • History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example, monoclonal antibody) or to any of the study drug .
  • Any issue, based on investigator judgement.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
941 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Nemolizumab

    Nemolizumab Active

    Drug: Nemolizumab

Interventions

  • DrugPlacebo

    Placebo

  • Nemolizumab

    Also known as: CD14152

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population

    IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.

    Time frame: Week 16

  2. Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population

    IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.

    Time frame: Week 16

  3. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population

    EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.

    Time frame: Week 16

  4. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population

    EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.

    Time frame: Week 16

  2. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.

    Time frame: Week 16

  3. Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 16

  4. Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 16

  5. Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 16

  6. Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 16

  7. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 4

  8. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 4

  9. Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 4

  10. Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 4

  11. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 2

  12. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 2

  13. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 1

  14. Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population

    The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

    Time frame: Week 1

07

Results

Posted Aug 14, 2024

Participant flow

The study was conducted at 177 active sites in Australia, Austria, Canada, Czech Republic, Germany, Great Britain, Korea, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain and the United States from 27 June 2019 to 11 August 2022.

Initial Treatment(Day 1-Week 16 Predose)
Participant flow — Initial Treatment(Day 1-Week 16 Predose)
MilestoneInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4WMaintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W
Started3216200000
Safety population3216160000
Completed2965600000
Not completed25600000
Withdrew: Pregnancy020000
Withdrew: Lack of efficacy250000
Withdrew: Adverse event990000
Withdrew: Subjects request11250000
Withdrew: Lost to follow-up0100000
Withdrew: Protocol deviation340000
Withdrew: Physician/principal investigators decision010000
Withdrew: Randomized but not treated040000
Maintenance Period (Week 16-Week 48)
Participant flow — Maintenance Period (Week 16-Week 48)
MilestoneInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4WMaintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W
Started00909191100
Safety population00919091100
Completed0076796982
Not completed0014122218
Withdrew: Lack of efficacy0043124
Withdrew: Adverse event001311
Withdrew: Subjects request006459
Withdrew: Lost to follow-up000111
Withdrew: Protocol deviation001010
Withdrew: Physician/pi decision002112
Withdrew: Other000011

Outcome measures

PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population

IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of atopic dermatitis (AD) and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population24.635.6
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = 0.0003 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 11.5 · 97.5% CI 4.7 to 18.3
PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population

IGA success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement from baseline to Week 16. The IGA is a 5-point scale ranging from 0 (clear) to 4 (severe) used by the Investigator or trained designee to evaluate the global severity of AD and the clinical response to treatment. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered a treatment failure. Participants with missing data at Week 16 were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a >= 2-point Reduction): Severe Pruritus Population21.435.5
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = 0.0002 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 14.3 · 97.5% CI 6.1 to 22.5
PrimaryPercentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population

EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD(erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT Population29.043.5
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 14.9 · 97.5% CI 7.8 to 22.0
PrimaryPercentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population

EASI-75 was defined as \>=75 percent(%) improvement in EASI from baseline to Week 16. EASI evaluates severity of participants AD based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification)scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data at Week 16 were considered non-responders. EASI total score is composite score ranging from 0 to 72. Higher scores represent greater severity of AD.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at 16: Severe Pruritus Population23.841.6
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 18.1 · 97.5% CI 9.6 to 26.6
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: ITT Population17.842.7
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 24.9 · 97.5% CI 18.4 to 31.5
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 28.1 · 97.5% CI 22.0 to 34.3The estimates are from 50 complete datasets by MI-MAR assumption.
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 16: Severe Pruritus Population18.646.1
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\].) · Strata-adjusted percentage difference: 27.5 · 97.5% CI 19.4 to 35.7
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\].) · Strata-adjusted percentage difference: 32.1 · 97.5% CI 24.4 to 39.8The estimates are from 50 complete datasets by MI-MAR assumption.
SecondaryPercentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: ITT Population11.230.6
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 19.5 · 97.5% CI 13.7 to 25.2
SecondaryPercentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With <2 Points in Weekly Average PP NRS at Week 16: Severe Pruritus Population7.627.8
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 20.3 · 97.5% CI 13.8 to 26.8
SecondaryPercentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of subjects
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population
percentage of subjectsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: ITT Population19.937.9
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 17.9 · 97.5% CI 11.3 to 24.5
SecondaryPercentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following question in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Weekly average SD NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With an Improvement of Sleep Disturbance Numeric Rating Scale (SD NRS) >=4 at Week 16: Severe Pruritus Population22.442.1
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 19.7 · 97.5% CI 11.2 to 28.2
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: ITT Population6.527.4
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 20.9 · 97.5% CI 15.8 to 26
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 4: Severe Pruritus Population7.128.3
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 21.2 · 97.5% CI 14.8 to 27.6
SecondaryPercentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: ITT Population3.716.0
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 12.2 · 97.5% CI 8.2 to 16.3
SecondaryPercentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Peak Pruritus Numeric Rating Scale (PP NRS) <2 at Week 4: Severe Pruritus Population2.912.6
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 9.7 · 97.5% CI 5.2 to 14.2
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: ITT Population3.117.7
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 14.6 · 97.5% CI 10.6 to 18.7
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 2: Severe Pruritus Population3.820.7
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = <0.0001 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 16.9 · 97.5% CI 11.5 to 22.3
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: ITT Population1.24.5
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = 0.0064 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\] and PP NRS \[\>=7, \<7\]).) · Strata-adjusted percentage difference: 3.4 · 97.5% CI 1.1 to 5.8
SecondaryPercentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population

The PP NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours on a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'. Weekly average PP NRS score was calculated using 7 consecutive days diary data and set to missing if less than 4 days data available. If a participant received any rescue therapy, the data after receipt of rescue therapy was considered treatment failure. Participants with missing data were considered non-responders.

Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population
percentage of participantsInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg
Percentage of Participants With Improvement of >=4 Points in Weekly Average Peak Pruritus Numeric Rating Scale (PP NRS) at Week 1: Severe Pruritus Population1.96.2
Statistical analysis
  • Initial Treatment Period (Baseline - Week 16 Predose): Placebo vs Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg · Cochran-Mantel-Haenszel · p = 0.0177 (Strata-adjusted p-values were calculated from Cochran-Mantel-Haenszel test adjusting randomized stratification variables (IGA severity \[3=moderate, 4=severe\]).) · Strata-adjusted percentage difference: 4.3 · 97.5% CI 0.9 to 7.7

Adverse events

Collected over Initial Treatment Period: From baseline to Week 16 pre-dose; Maintenance Period: From end of Initial Treatment Period (i.e., Week 16) to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Treatment Period (Baseline - Week 16 Predose): Placebo0/321 (0%)4/321 (1.2%)67/321 (20.9%)
Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg0/616 (0%)6/616 (1%)144/616 (23.4%)
Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4W0/91 (0%)4/91 (4.4%)27/91 (29.7%)
Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8W0/90 (0%)3/90 (3.3%)28/90 (31.1%)
Maintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4W0/91 (0%)2/91 (2.2%)33/91 (36.3%)
Maintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W0/100 (0%)1/100 (1%)35/100 (35%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4WMaintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W
CellulitisInfections and infestations0/3210/6160/911/900/910/100
Splenic injuryInjury, poisoning and procedural complications0/3210/6160/911/900/910/100
AnxietyPsychiatric disorders0/3210/6160/911/900/910/100
GoitreEndocrine disorders0/3210/6160/910/901/910/100
AppendicitisInfections and infestations0/3210/6161/910/900/910/100
COVID-19Infections and infestations0/3210/6161/910/900/910/100
ErysipelasInfections and infestations0/3210/6160/910/901/910/100
Dupuytren's contractureMusculoskeletal and connective tissue disorders0/3210/6161/910/900/910/100
PeriarthiritisMusculoskeletal and connective tissue disorders0/3210/6161/910/900/910/100
Plasmablastic lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3210/6160/910/901/910/100
Most frequent other events
Most frequent other events
EventInitial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q4WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Q8WMaintenance Period (Week 16-Week 48): Nemolizumab 30 mg Q4W to Placebo Q4WMaintenance Period (Week 16-Week 48): Placebo Q4W Re-assigned to Placebo Q4W
Dermatitis atopicSkin and subcutaneous tissue disorders33/32173/6167/918/9012/9110/100
COVID-19Infections and infestations6/32110/6169/919/906/9110/100
Upper respiratory tract infectionInfections and infestations14/3219/6163/913/905/919/100
NasopharyngitisInfections and infestations8/3219/6167/915/907/916/100
AsthmaRespiratory, thoracic and mediastinal disorders13/32133/6163/916/905/915/100
HeadacheNervous system disorders11/32128/6165/915/903/911/100

Baseline characteristics

The ITT population consisted of all randomized participants.

Age, Continuous
Age, Continuous(years)Initial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgTotal
Mean33.3 ± 15.6133.5 ± 15.9233.3 ± 17.5
Sex: Female, Male
Sex: Female, Male(Participants)Initial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgTotal
Female144297441
Male177323500
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Initial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgTotal
Hispanic or Latino326496
Not Hispanic or Latino288552840
Unknown or Not Reported145
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Initial Treatment Period (Baseline - Week 16 Predose): PlaceboInitial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mgTotal
American Indian or Alaska Native325
Asian51117168
Native Hawaiian or Other Pacific Islander011
Black or African American183654
White244451695
More than one race41014
Unknown or Not Reported134
08

Study locations

174 sites
  • Galderma Investigational Site 8880
    North Little Rock, Arkansas 72117, United States
  • Galderma Investigational Site 8578
    Cerritos, California 90703, United States
  • Galderma Investigational Site 8636
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site 8888
    Fullerton, California 92835, United States
  • Galderma Investigational Site 8686
    Lomita, California 90717, United States
  • Galderma Investigational Site 8674
    Los Angeles, California 90025, United States
  • Galderma Investigational Site 8125
    San Francisco, California 94115, United States
  • Galderma Investigational Site 8895
    Santa Ana, California 92703, United States
  • Galderma Investigational Site 8608
    Santa Monica, California 90404, United States
  • Galderma Investigational Site 8897
    Brandon, Florida 33511, United States
  • Galderma Investigational Site 8805
    Cape Coral, Florida 33991, United States
  • Galderma Investigational Site 8902
    Doral, Florida 33122, United States
  • Galderma Investigational Site 8804
    Hialeah, Florida 33016, United States
  • Galderma Investigational Site 8711
    Jacksonville, Florida 32256, United States
  • Galderma Investigational Site 8806
    Miami Lakes, Florida 33014, United States
  • Galderma Investigational Site 8800
    Miami Lakes, Florida 33016, United States
  • Galderma Investigational Site 8710
    Miami, Florida 33126, United States
  • Galderma Investigational Site 8801
    Miami, Florida 33145, United States
  • Galderma Investigational Site 8737
    Miami, Florida 33174, United States
  • Galderma Investigational Site 8708
    Miami, Florida 33176, United States
  • Galderma Investigational Site 8734
    Pembroke Pines, Florida 33028, United States
  • Galderma Investigational Site 8744
    Macon, Georgia 31217, United States
  • Galderma Investigational Site 8728
    Newnan, Georgia 30263, United States
  • Galderma Investigational Site 8887
    Union City, Georgia 30291, United States
  • Galderma Investigational Site 8890
    Blackfoot, Idaho 83221, United States
  • Galderma Investigational Site 8819
    Nampa, Idaho 83687, United States
  • Galderma Investigational Site 8571
    Skokie, Illinois 60076, United States
  • Galderma Investigational Site 8712
    Skokie, Illinois 60077, United States
  • Galderma Investigational Site 8142
    Indianapolis, Indiana 46250, United States
  • Galderma Investigational Site 8771
    Louisville, Kentucky 40241, United States
  • Galderma Investigational Site 8882
    Bangor, Maine 04401, United States
  • Galderma Investigational Site 8743
    Ann Arbor, Michigan 48109, United States
  • Galderma Investigational Site 8512
    Bay City, Michigan 48706, United States
  • Galderma Investigational Site 8155
    Troy, Michigan 48084, United States
  • Galderma Investigational Site 8748
    Ypsilanti, Michigan 48197, United States
  • Galderma Investigational Site 8521
    Saint Joseph, Missouri 64506, United States
  • Galderma Investigational Site 8718
    Missoula, Montana 59808, United States
  • Galderma Investigational Site 8810
    Omaha, Nebraska 68144, United States
  • Galderma Investigational Site 8740
    Henderson, Nevada 89052, United States
  • Galderma Investigational Site 8242
    Brooklyn, New York 11203, United States
  • Galderma Investigational Site 8620
    New York, New York 10023, United States
  • Galderma Investigational Site 8279
    New York, New York 10075, United States
  • Galderma Investigational Site 8648
    Wilmington, North Carolina 28405, United States
  • Galderma Investigational Site 8702
    Bexley, Ohio 43209, United States
  • Galderma Investigational Site 8595
    Dublin, Ohio 43016, United States
  • Galderma Investigational Site 8206
    Norman, Oklahoma 73071, United States
  • Galderma Investigational Site 8857
    Oklahoma City, Oklahoma 73118, United States
  • Galderma Investigational Site 8255
    Philadelphia, Pennsylvania 19103, United States
  • Galderma Investigational Site 8802
    Plymouth Meeting, Pennsylvania 19462, United States
  • Galderma Investigational Site 8736
    Charleston, South Carolina 29425, United States
  • Galderma Investigational Site 8818
    Rapid City, South Dakota 57702, United States
  • Galderma Investigational Site 8133
    Arlington, Texas 76011, United States
  • Galderma Investigational Site 8238
    Dallas, Texas 75230, United States
  • Galderma Investigational Site 8827
    Dripping Springs, Texas 78620, United States
  • Galderma Investigational Site 8664
    Frisco, Texas 75034, United States
  • Galderma Investigational Site 8042
    Houston, Texas 77056, United States
  • Galderma Investigational Site 8862
    Fairfax, Virginia 22031, United States
  • Galderma Investigational Site 5441
    Darlinghurst, New South Wales 2010, Australia
  • Galderma Investigational Site 5759
    Kogarah, New South Wales 2217, Australia
  • Galderma Investigational Site 6152
    Westmead, New South Wales 2145, Australia
  • Galderma Investigational Site 5638
    Benowa, Queensland 4217, Australia
  • Galderma Investigational Site 6161
    Brisbane, Queensland 4102, Australia
  • Galderma Investigational Site 6159
    Woodville, South Australia 5011, Australia
  • Galderma Investigational Site 6131
    Carlton, Victoria 3053, Australia
  • Galderma Investigational Site 5366
    East Melbourne, Victoria 3002, Australia
  • Galderma Investigational Site 5458
    Parkville, Victoria 3050, Australia
  • Galderma Investigational Site 5453
    Fremantle, Western Australia 6160, Australia
  • Galderma Investigational Site 6153
    Victoria Park, Western Australia 6100, Australia
  • Galderma Investigational Sites 6157
    Graz, Styria 8036, Austria
  • Galderma Investigational Site 6194
    Vienna, Wien 1090, Austria
  • Galderma Investigational Site 6158
    Vienna, 1220, Austria
  • Galderma Investigational Site 8085
    Calgary, Alberta T2G 1B1, Canada
  • Galderma Investigational Site 8903
    Calgary, Alberta T2J 7E1, Canada
  • Galderma Investigational Site 8215
    Calgary, Alberta T3E 0B2, Canada
  • Galderma Investigational Site 8088
    Edmonton, Alberta T5J 3S9, Canada
  • Galderma Investigational Site 8824
    Edmonton, Alberta T6G 1C3, Canada
  • Galderma Investigational Site 8722
    Edmonton, Alberta T6G 1C9, Canada
  • Galderma Investigational Site 8161
    Surrey, British Columbia V3V 0C6, Canada
  • Galderma Investigational Site 8586
    Barrie, Ontario L4M 7G1, Canada
  • Galderma Investigational Site 8904
    Guelph, Ontario N1L 0B7, Canada
  • Galderma Investigational Site 8901
    Ottawa, Ontario K1H7X3, Canada
  • Galderma Investigational Site 8336
    Toronto, Ontario M3H 5Y8, Canada
  • Galderma Investigational Site 8899
    Toronto, Ontario M4W 2N4, Canada
  • Galderma Investigational Site 8780
    Niagara Falls, L2H 1H5, Canada
  • Galderma Investigational Site 8610
    Ottawa, K1G 6C6, Canada
  • Galderma Investigational Site 8000
    Saint John, A1C2H5, Canada
  • Galderma Investigational Site 8731
    Waterloo, N2J 1C4, Canada
  • Galderma Investigational Site 6055
    Brno, 656 91, Czechia
  • Galderma Investigational Site 5225
    Náchod, 547 01, Czechia
  • Galderma Investigational Site 6030
    Olomouc, 779 00, Czechia
  • Galderma Investigational Site 6024
    Prague, 100 00, Czechia
  • Galderma Investigational Site 6240
    Prague, 120 00, Czechia
  • Galderma Investigational Site 6054
    Praha, 110 00, Czechia
  • Galderma Investigational Site 6021
    Praha, 11000, Czechia
  • Galderma Investigational Site 6025
    Praha, 150 06, Czechia
  • Galderma Investigational Site 6146
    Langenau, Hesse 89129, Germany
  • Galderma Investigational Site 6214
    Tuebingen, Niedersachesen 72076, Germany
  • Galderma Investigational Site 6172
    Berlin, NRW 12203, Germany
  • Galderma Investigational Site 5437
    Kiel, Schleswig-Holst 24105, Germany
  • Galderma Investigational Site 6022
    Bad Bentheim, 48455, Germany

Showing the first 100 of 174 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Dec 2021, 30 months.

Results were first posted in Aug 2024, 2 years 7 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 30 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2019
First posted
Jun 14, 2019
StartActual
Jun 27, 2019
Primary completionActual
Dec 29, 2021
CompletionActual
Aug 11, 2022
Results first posted
Aug 14, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03985943
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Jun 27, 2019
Primary completion
Dec 29, 2021
Completion
Aug 11, 2022
Results posted
Aug 14, 2024
Last update
Aug 14, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion